Antiproliferative and antimigratory actions of synthetic long chain n-3 monounsaturated fatty acids in breast cancer cells that overexpress cyclooxygenase-2

Journal of Medicinal Chemistry

Volumn 55, Issue 16, 2012, Pages 7163-7172

  Cui, Pei H ^a   Kirsi Bourget, Tristan Rawing ^a   Kim, Terry ^a   Duke, Colin C ^a   Doddareddy, Munikumar R ^a   Hibbs, David E ^a   Zhou, Fanfan ^a   Tattam, Bruce N ^a   Petrovic, Nenad ^b   Murray, Michael ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKENE DERIVATIVE; ARACHIDONIC ACID; ARGININE; CYCLOOXYGENASE 2; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PROSTAGLANDIN E2; TYROSINE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CHEMICAL BOND; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; HYDROPHOBICITY; MOLECULAR DOCKING; MOLECULAR MODEL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; CYCLOOXYGENASE 2; DINOPROSTONE; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LAMININ; MODELS, MOLECULAR; NEOPLASM INVASIVENESS; PROTEOGLYCANS; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 84866911131     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300673z     Document Type: Article

References (47)

1. Mehlen, P.; Puisieux, A. Metastasis: a question of life or death. Nat. Rev. Cancer 2006, 6, 449-458.
2. Borst, P.; Jonkers, J.; Rottenberg, S. What makes tumors multidrug resistant? Cell Cycle 2007, 6, 2782-2787.
3. Maillard, V.; Bougnoux, P.; Ferrari, P.; Jourdan, M. L.; Pinault, M.; Lavillonniere, F.; Body, G.; Le Floch, O; Chajes, V. N-3 and N-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in Tours, France. Int. J. Cancer 2002, 98, 78-83.
4. Rose, D. P.; Connolly, J. M.; Rayburn, J.; Coleman, M. Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice. J. Natl. Cancer Inst. 1995, 87, 587-592.
5. Rose, D. P.; Connolly, J. M.; Coleman, M. Effect of omega-3 fatty acids on the progression of metastases after the surgical excision of human breast cancer cell solid tumors growing in nude mice. Clin. Cancer Res. 1996, 2, 1751-1756.
6. 2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br. J. Cancer 1995, 72, 1412-1419.
7. 2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl. Acad. Sci. U.SA. 2004, 101, 591-596.
8. Hwang, D.; Scollard, D.; Byrne, J.; Levine, E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 1998, 90, 455-460.
9. Hla, T.; Bishop-Bailey, D.; Liu, C. H; Schaefers, H; Trifan, O. C. Cyclooxygenase-1 and -2 isoenzymes. Int. J. Biochem. Cell Biol. 1999, 31, 551-557.
10. Half, E.; Tang, X. M.; Gwyn, K.; Sahin, A.; Wathen, K.; Sinicrope, F. A Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002, 62, 1676-1681.
11. Rozic, J. G.; Chakraborty, C; Lala, P. K. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int. J. Cancer 2001, 93, 497-506.
12. Basu, G. D.; Pathangey, L. B.; Tinder, T. L.; Lagioia, M.; Gendler, S. J.; Mukherjee, P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol. Cancer Res. 2004, 2, 632-642.
13. Connolly, E. M.; Harmey, J. H; O'Grady, T.; Foley, D.; Roche-Nagle, G.; Kay, E.; Bouchier-Hayes, D. J. Cyclo-oxygenase inhibition reduces tumor growth and metastasis in an orthotopic model of breast cancer. Br. J. Cancer 2002, 87, 231-237.
14. Rao, C. V.; Reddy, B. S. NSAIDs and chemoprevention. Curr. Cancer Drug Targets 2004, 4, 29-42.
15. Rawling, T.; Duke, C. C; Cui, P. H; Murray, M. Facile and stereoselective synthesis of (Z)-15-octadecenoic acid and (Z)-16-nonadecenoic acid: monounsaturated omega-3 fatty acids. Lipids 2010, 45, 159-165.
16. Organ, M. G.; Avola, S.; Dubovyk, I.; Hadei, N.; Kantchev, E. A.; O'Brien, C. J.; Valente, C. A user-friendly, all-purpose Pd-NHC-(NHC=N- heterocyclic carbene) precatalyst for the Negishi reaction: a step towards a universal cross-coupling catalyst. Chem.-Eur. J. 2006, 12, 4749-4755.
17. Backeberg, O. G.; Staskun, B. A novel reduction of nitriles to aldehydes. J. Chem. Soc. 1962, 3961-3963.
18. Heffner, R J.; Jiang, J.; Joullie, M. M. Total synthesis of (-)-nummularine F. J. Am. Chem. Soc. 1992, 114, 10181 - 10189.
19. Szymczak, M.; Murray, M.; Petrovic, N. Modulation of angiogenesis by a〉-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood 2008, 111, 3514-3521.
20. 2 production and COX-2 protein levels in MDA-MB-231 breast cancer cell cultures. J. Nutr. Biochem. 2005, 16, 184-192.
21. 2 regulates the angiogenic switch. Proc. Natl. Acad. Sci. U.SA. 2004, 101, 415-416.
22. Petrovic, N.; Murray, M. Using N, N, N', N'-tetramethyl-p- phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro. Methods Mol. Biol. 2010, 594, 129-140.
23. Bhattacharyya, D. K.; Lecomte, M.; Rieke, C. J.; Garavito, M.; Smith, W. L. Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J. Biol. Chem. 1996, 271, 2179-2184.
24. Rowlinson, S. W.; Kiefer, J. R; Prusakiewicz, J. J.; Pawlitz, J. L.; Kozak, K R; Kalgutkar, A. S.; Stallings, W. C.; Kurumbail, R G; Marnett, L. J. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J. Biol. Chem. 2003, 278, 45763-45769.
25. Ristimaki, A.; Sivula, A.; Lundin, J.; Lundin, M.; Salminen, T.; Haglund, C.; Joensuu, H; Isola, J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62, 632-635.
26. Subbaramaiah, K.; Norton, L.; Gerald, W.; Dannenberg, A. J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 2002, 277, 18649-18657.
27. Liu, X. H.; Rose, D. P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996, 56, 5125-5127.
28. Takahashi, Y. K. F.; Noguchi, M.; Miwa, K.; Sato, H.; Seiki, M.; Inoue, H.; Tanabe, T.; Yoshimoto, T. Activation of matrix metal-loproteinase-2 in human breast cancer cells overexpressing cyclo-oxygenase-1 or -2. FEBS Lett. 1999, 460, 145-148.
29. Sharpe, C. R.; Collet, J. P.; McNutt, M.; Belzile, E.; Boivin, J. F.; Hanley, J. A. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br. J. Cancer 2000, 83, 112-120.
30. Davies, G.; Salter, J.; Hills, M.; Martin, L. A.; Sacks, N.; Dowsett, M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin. Cancer Res. 2003, 9, 2651-2656.
31. Harris, R. E.; Chlebowski, R. T.; Jackson, R. D.; Frid, D. J.; Ascenseo, J. L.; Anderson, G.; Loar, A.; Rodabough, R. J.; White, E.; McTiernan, A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003, 63, 6096-6101.
32. Giovannucci, E.; Egan, K. M.; Hunter, D. J.; Stampfer, M. J.; Colditz, G. A.; Willett, W. C.; Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 1995, 333, 609-614.
33. Basu, G. D.; Pathangey, L. B.; Tinder, T. L.; Gendler, S. J.; Mukherjee, P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005, 7, R422-R435.
34. Minoura, T.; Takata, T.; Sakaguchi, M.; Takada, H.; Yamamura, M.; Hioki, K.; Yamamoto, M. Effect of dietary eicosapentaenoic acid on azoxymethane-induced colon carcinogenesis in rats. Cancer Res. 1988, 48, 4790-4794.
35. Begin, M. E.; Ells, G.; Horrobin, D. F. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J. Natl Cancer Inst. 1988, 80, 188-194.
36. Falconer, J. S.; Ross, J. A.; Fearon, K. C.; Hawkins, R. A.; O'Riordain, M. G.; Carter, D. C. Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br. J. Cancer 1994, 69, 826-832.
37. Palomer, A.; Cabre, F.; Pascual, J.; Campos, J.; Trujillo, M. A.; Entrena, A.; Gallo, M. A.; García, L; Mauleon, D.; Espinosa, A. Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J. Med. Chem. 2002, 45, 1402-1411.
38. Rowlinson, S. W.; Crews, B. C.; Lanzo, C. A.; Marnett, L. J. The binding of arachidonic acid in the cyclooxygenase active site of mouse prostaglandin endoperoxide synthase-2 (COX-2). A putative L-shaped binding conformation utilizing the top channel region. J. Biol. Chem. 1999, 274, 23305-23310.
39. Vecchio, A. J.; Simmons, D. M.; Malkowski, M. G. Structural basis of fatty acid substrate binding to cyclooxygenase-2. J. Biol. Chem. 2010, 285, 22152-22163.
40. Kiefer, J. R.; Pawlitz, J. L.; Moreland, K. T.; Stegeman, R. A.; Hood, W. F.; Gierse, J. K.; Stevens, A. M.; Goodwin, D. C.; Rowlinson, S. W.; Marnett, L. J.; Stallings, W. C.; Kurumbail, R. G. Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 2000, 405, 97-101.
41. Dong, L.; Vecchio, A. J.; Sharma, N. P.; Jurban, B. J.; Malkowski, M. G.; Smith, W. L. Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J. Biol. Chem. 2011, 286, 19035-19046.
42. Picot, D.; Loll, P. J.; Garavito, R. M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994, 367, 243-249.
43. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384, 644-648.
44. Duffy, P. E.; Quinn, S. M.; Roche, H. M.; Evans, P. Synthesis of trans-vaccenic acid and cis-9-trans-11-conjugated linoleic acid. Tetrahedron 2006, 62, 4838-4843.
45. 1H-NMR studies. Helv. Chim. Acta 1975, 58, 1551-1559.
46. Zhou, J.; Fu, G. C. Palladium-catalyzed Negishi cross-coupling reactions of unactivated alkyl iodides, bromides, chlorides, and tosylates. J. Am. Chem. Soc. 2003, 125, 12527-12530.
47. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49, 6177-6196.